Related Experiment Videos
Intramuscular beta interferon for chronic hepatitis C: is it worth trying?
E Fesce1, A Airoldi, L Mondazzi
1Niguarda Cà Granda Hospital, Milan, Italy.
Italian Journal of Gastroenterology and Hepatology
|July 24, 1998
Summary
Higher doses of beta interferon showed a better short-term response in chronic hepatitis C patients. However, sustained response was minimal, and high costs may limit clinical use.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Intramuscular beta interferon showed limited efficacy for chronic hepatitis C at standard doses.
- Low bioavailability may explain the lack of effectiveness of previous intramuscular beta interferon treatments.
Purpose of the Study:
- To evaluate the efficacy of a higher dosage of intramuscular beta interferon in treating chronic hepatitis C.
- To determine if increased dosage improves short-term and long-term treatment response.
Main Methods:
- A randomized trial involving 92 patients with chronic hepatitis C.
- Patients received either 3 or 6 million units of natural human fibroblast beta interferon intramuscularly three times weekly for 12 months.
Main Results:
- The higher dosage group (6 million units) demonstrated a significantly higher short-term biochemical response rate (21% vs. 4.5%, p < 0.05).
- A sustained biochemical response was achieved in only one patient (2%) in the higher dosage group.
Conclusions:
- Increased intramuscular beta interferon dosage improves short-term response in chronic hepatitis C.
- Sustained response remains low, and high treatment costs may impede the cost-effectiveness of high-dose beta interferon therapy.